MD4327866T2 - Mirikizumab în tratarea colitei ulcerative - Google Patents
Mirikizumab în tratarea colitei ulcerativeInfo
- Publication number
- MD4327866T2 MD4327866T2 MDE20241003T MDE20241003T MD4327866T2 MD 4327866 T2 MD4327866 T2 MD 4327866T2 MD E20241003 T MDE20241003 T MD E20241003T MD E20241003 T MDE20241003 T MD E20241003T MD 4327866 T2 MD4327866 T2 MD 4327866T2
- Authority
- MD
- Moldova
- Prior art keywords
- mirikizumab
- administered
- dose
- induction
- doses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650314P | 2018-03-30 | 2018-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD4327866T2 true MD4327866T2 (ro) | 2026-04-30 |
Family
ID=66429483
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20241003T MD4327866T2 (ro) | 2018-03-30 | 2019-03-28 | Mirikizumab în tratarea colitei ulcerative |
| MDE20210135T MD3773715T2 (ro) | 2018-03-30 | 2019-03-28 | Mirikizumab în tratamentul colitei ulcerative |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20210135T MD3773715T2 (ro) | 2018-03-30 | 2019-03-28 | Mirikizumab în tratamentul colitei ulcerative |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US12152072B2 (https=) |
| EP (2) | EP4327866B1 (https=) |
| JP (4) | JP7119114B2 (https=) |
| KR (1) | KR102552693B1 (https=) |
| CN (1) | CN111936165A (https=) |
| AU (2) | AU2019243283C1 (https=) |
| BR (1) | BR112020018099A2 (https=) |
| CA (1) | CA3095297A1 (https=) |
| DK (2) | DK3773715T3 (https=) |
| EA (1) | EA202091989A1 (https=) |
| ES (2) | ES3063700T3 (https=) |
| FI (2) | FI4327866T3 (https=) |
| HR (2) | HRP20260275T1 (https=) |
| HU (1) | HUE067445T2 (https=) |
| IL (2) | IL277514B2 (https=) |
| LT (2) | LT3773715T (https=) |
| MA (2) | MA52216B1 (https=) |
| MD (2) | MD4327866T2 (https=) |
| MX (1) | MX2020010269A (https=) |
| MY (1) | MY202368A (https=) |
| PL (2) | PL4327866T3 (https=) |
| PT (2) | PT4327866T (https=) |
| RS (2) | RS67806B1 (https=) |
| SG (1) | SG11202009526RA (https=) |
| SI (2) | SI3773715T1 (https=) |
| TW (2) | TWI744617B (https=) |
| UA (1) | UA128578C2 (https=) |
| WO (1) | WO2019191464A1 (https=) |
| ZA (1) | ZA202005388B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7805788B2 (ja) | 2019-05-23 | 2026-01-26 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 |
| BR112022015996A2 (pt) * | 2020-02-14 | 2022-10-11 | Janssen Biotech Inc | Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 |
| IL298389A (en) | 2020-05-21 | 2023-01-01 | Janssen Biotech Inc | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| JP7423815B2 (ja) * | 2020-10-20 | 2024-01-29 | セトラスホールディングス株式会社 | 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム |
| TW202241506A (zh) * | 2021-01-06 | 2022-11-01 | 美商艾伯維有限公司 | 治療克羅恩氏病及潰瘍性結腸炎之方法 |
| BR112023024064A2 (pt) * | 2021-05-20 | 2024-01-30 | Janssen Biotech Inc | Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa |
| JP2024521748A (ja) * | 2021-05-28 | 2024-06-04 | イーライ リリー アンド カンパニー | 潰瘍性大腸炎に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体調節 |
| US20230159633A1 (en) * | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
| AU2023383916A1 (en) * | 2022-11-22 | 2025-07-10 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
| TW202500184A (zh) | 2023-03-10 | 2025-01-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
| CN121443635A (zh) * | 2023-06-16 | 2026-01-30 | 信达生物医药科技(杭州)有限公司 | 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途 |
| WO2025170982A2 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2026060205A1 (en) | 2024-09-13 | 2026-03-19 | Eli Lilly And Company | PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2452694T1 (sl) * | 2005-06-30 | 2019-05-31 | Janssen Biotech, Inc. | Protitelesa proti-IL-23, sestavki in postopki uporabe |
| HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-IL-23 antibodies, preparations, methods and applications |
| ES2708988T3 (es) | 2007-02-23 | 2019-04-12 | Merck Sharp & Dohme | Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética |
| JP2012507723A (ja) * | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| MX2019000046A (es) * | 2010-11-04 | 2023-10-05 | Boehringer Ingelheim Int | Anticuerpos anti-il-23. |
| AR094877A1 (es) | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
| US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| MX2020009265A (es) * | 2018-03-05 | 2020-10-01 | Janssen Biotech Inc | Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23. |
-
2019
- 2019-03-27 TW TW108110767A patent/TWI744617B/zh active
- 2019-03-27 TW TW110139868A patent/TWI837532B/zh active
- 2019-03-28 ES ES23215626T patent/ES3063700T3/es active Active
- 2019-03-28 RS RS20260242A patent/RS67806B1/sr unknown
- 2019-03-28 ES ES19722256T patent/ES2983809T3/es active Active
- 2019-03-28 CA CA3095297A patent/CA3095297A1/en active Pending
- 2019-03-28 AU AU2019243283A patent/AU2019243283C1/en active Active
- 2019-03-28 PL PL23215626.5T patent/PL4327866T3/pl unknown
- 2019-03-28 BR BR112020018099-8A patent/BR112020018099A2/pt unknown
- 2019-03-28 PT PT232156265T patent/PT4327866T/pt unknown
- 2019-03-28 EA EA202091989A patent/EA202091989A1/ru unknown
- 2019-03-28 LT LTEPPCT/US2019/024633T patent/LT3773715T/lt unknown
- 2019-03-28 HR HRP20260275TT patent/HRP20260275T1/hr unknown
- 2019-03-28 DK DK19722256.5T patent/DK3773715T3/da active
- 2019-03-28 SI SI201930750T patent/SI3773715T1/sl unknown
- 2019-03-28 US US16/981,915 patent/US12152072B2/en active Active
- 2019-03-28 CN CN201980023563.3A patent/CN111936165A/zh active Pending
- 2019-03-28 EP EP23215626.5A patent/EP4327866B1/en active Active
- 2019-03-28 FI FIEP23215626.5T patent/FI4327866T3/fi active
- 2019-03-28 DK DK23215626.5T patent/DK4327866T3/da active
- 2019-03-28 MD MDE20241003T patent/MD4327866T2/ro unknown
- 2019-03-28 FI FIEP19722256.5T patent/FI3773715T3/fi active
- 2019-03-28 WO PCT/US2019/024633 patent/WO2019191464A1/en not_active Ceased
- 2019-03-28 PL PL19722256.5T patent/PL3773715T3/pl unknown
- 2019-03-28 SI SI201931019T patent/SI4327866T1/sl unknown
- 2019-03-28 MA MA52216A patent/MA52216B1/fr unknown
- 2019-03-28 UA UAA202005571A patent/UA128578C2/uk unknown
- 2019-03-28 RS RS20240698A patent/RS65661B1/sr unknown
- 2019-03-28 MD MDE20210135T patent/MD3773715T2/ro unknown
- 2019-03-28 JP JP2020552872A patent/JP7119114B2/ja active Active
- 2019-03-28 IL IL277514A patent/IL277514B2/en unknown
- 2019-03-28 IL IL312807A patent/IL312807B2/en unknown
- 2019-03-28 SG SG11202009526RA patent/SG11202009526RA/en unknown
- 2019-03-28 MA MA67901A patent/MA67901B1/fr unknown
- 2019-03-28 MX MX2020010269A patent/MX2020010269A/es unknown
- 2019-03-28 HU HUE19722256A patent/HUE067445T2/hu unknown
- 2019-03-28 KR KR1020207027982A patent/KR102552693B1/ko active Active
- 2019-03-28 PT PT197222565T patent/PT3773715T/pt unknown
- 2019-03-28 HR HRP20240904TT patent/HRP20240904T1/hr unknown
- 2019-03-28 LT LTEP23215626.5T patent/LT4327866T/lt unknown
- 2019-03-28 MY MYPI2020004942A patent/MY202368A/en unknown
- 2019-03-28 EP EP19722256.5A patent/EP3773715B1/en active Active
-
2020
- 2020-08-28 ZA ZA2020/05388A patent/ZA202005388B/en unknown
-
2022
- 2022-08-03 JP JP2022123689A patent/JP7331219B2/ja active Active
-
2023
- 2023-08-09 JP JP2023130117A patent/JP7571225B2/ja active Active
- 2023-10-11 AU AU2023248103A patent/AU2023248103B2/en active Active
-
2024
- 2024-10-09 JP JP2024176901A patent/JP2025020134A/ja active Pending
- 2024-10-16 US US18/917,597 patent/US20250034243A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023248103B2 (en) | Methods of treating ulcerative colitis | |
| Atreya et al. | IL-23 blockade in anti-TNF refractory IBD: from mechanisms to clinical reality | |
| Argollo et al. | Novel therapeutic targets for inflammatory bowel disease | |
| Neurath | Current and emerging therapeutic targets for IBD | |
| US20230070988A1 (en) | Combinations of egfr inhibitors and ror1 inhibitors for the treatment of cancer | |
| TWI842966B (zh) | 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途 | |
| CN119700968A (zh) | 用于治疗克罗恩氏病的方法中的米吉珠单抗 | |
| HK40101440A (en) | Mirikizumab in the treatment of ulcerative colitis | |
| HK40036550A (en) | Mirikizumab in the treatment of ulcerative colitis | |
| HK40036550B (en) | Mirikizumab in the treatment of ulcerative colitis | |
| EA049081B1 (ru) | Способы лечения язвенного колита | |
| Egan et al. | Re-defining outcomes and re-evaluating remission in inflammatory bowel disease: Assessing key evidence |